Related Experiment Video
Updated: Jul 6, 2026
08:52
Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells
Published on: June 13, 2018
Leukemic transformation of Langerhans cell sarcoma
Kousuke Sumida1, Yuya Yoshidomi1, Hiroko Koga1
1Department of Hematology, Saga Prefectural Hospital Koseikan, 1-12-9, Mizugae, Saga, 840-8571, Japan.
International Journal of Hematology
|March 25, 2008
Summary
Langerhans cell sarcoma can transform into leukemia, presenting a rare but aggressive clinical course. This leukemic phase requires careful differentiation from acute myelogenous leukemia.
Area of Science:
- Oncology
- Hematology
- Pathology
Background:
- Langerhans cell sarcoma (LCS) is a rare malignant proliferation of Langerhans cells.
- Immunophenotyping and histological analysis are crucial for LCS diagnosis.
Observation:
- A 57-year-old male presented with supraclavicular lymphadenopathy.
- Diagnosis of LCS was confirmed by CD1a, S-100, and langerin positivity with bizarre pleomorphism.
Findings:
- The patient developed a leukemic phase of LCS 3 months post-diagnosis.
- Leukemic cells expressed CD5, CD7, CD13, CD33, CD34, CD68, and CD123.
- Despite chemotherapy, the patient succumbed to the disease 7 months after initial diagnosis.
Implications:
- Leukemic transformation represents an advanced stage of LCS.
- Distinguishing leukemic LCS from acute myelogenous leukemia (AML) is critical for appropriate management.
- This case highlights the aggressive nature and potential for leukemic evolution in LCS.
